SH-111 Successful FDA pre-IND meeting

Shorla Oncology have completed a successful pre-IND meeting with the US Health Authority, the Food and Drug Administration (‘FDA’) on our oncology drug SH-111. This product will have a significant clinical benefit to children suffering from Leukaemia and Shorla are delighted to be supported by the Children’s Oncology Group (‘COG’) in the US in advocating for this much needed drug.